Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
21 10 2020
Historique:
received: 04 08 2020
accepted: 22 09 2020
entrez: 22 10 2020
pubmed: 23 10 2020
medline: 11 11 2020
Statut: epublish

Résumé

Clonal diversity is a consequence of cancer cell evolution driven by Darwinian selection. Precise characterization of clonal architecture is essential to understand the evolutionary history of tumor development and its association with treatment resistance. Here, using a single-cell DNA sequencing, we report the clonal architecture and mutational histories of 123 acute myeloid leukemia (AML) patients. The single-cell data reveals cell-level mutation co-occurrence and enables reconstruction of mutational histories characterized by linear and branching patterns of clonal evolution, with the latter including convergent evolution. Through xenotransplantion, we show leukemia initiating capabilities of individual subclones evolving in parallel. Also, by simultaneous single-cell DNA and cell surface protein analysis, we illustrate both genetic and phenotypic evolution in AML. Lastly, single-cell analysis of longitudinal samples reveals underlying evolutionary process of therapeutic resistance. Together, these data unravel clonal diversity and evolution patterns of AML, and highlight their clinical relevance in the era of precision medicine.

Identifiants

pubmed: 33087716
doi: 10.1038/s41467-020-19119-8
pii: 10.1038/s41467-020-19119-8
pmc: PMC7577981
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

5327

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA100632
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA193235
Pays : United States
Organisme : NIH HHS
ID : S10 OD024977
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA255721
Pays : United States

Commentaires et corrections

Type : ErratumIn
Type : ErratumIn

Références

Nature. 2019 Jul;571(7765):355-360
pubmed: 31270458
Cell. 2017 Feb 9;168(4):613-628
pubmed: 28187284
Cell. 2012 Jul 20;150(2):264-78
pubmed: 22817890
N Engl J Med. 2017 Feb 9;376(6):536-547
pubmed: 28177873
N Engl J Med. 2012 Mar 8;366(10):883-892
pubmed: 22397650
Blood. 2010 Aug 5;116(5):702-10
pubmed: 20413658
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Nature. 2015 Feb 19;518(7539):422-6
pubmed: 25470049
Mol Cell. 2015 May 21;58(4):598-609
pubmed: 26000845
Nat Methods. 2016 Jun;13(6):505-7
pubmed: 27088313
Cell. 2012 May 25;149(5):994-1007
pubmed: 22608083
Leukemia. 2011 Feb;25(2):246-53
pubmed: 21079611
Nature. 2010 Oct 28;467(7319):1109-13
pubmed: 20981101
Cancer Discov. 2019 Aug;9(8):1050-1063
pubmed: 31088841
Cancer Cell. 2014 Mar 17;25(3):379-92
pubmed: 24613412
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5
pubmed: 20837533
Nature. 2011 Jan 20;469(7330):356-61
pubmed: 21160474
Leukemia. 2019 May;33(5):1113-1123
pubmed: 30568172
Nat Rev Cancer. 2015 Mar;15(3):152-65
pubmed: 25693834
Genome Res. 2018 Sep;28(9):1345-1352
pubmed: 30087104
Cell. 2019 Mar 7;176(6):1265-1281.e24
pubmed: 30827681
Genome Biol. 2016 May 05;17:86
pubmed: 27149953
Nature. 2014 Feb 20;506(7488):328-33
pubmed: 24522528
Cell Stem Cell. 2018 Nov 1;23(5):700-713.e6
pubmed: 30388424
Nature. 2011 Apr 7;472(7341):90-4
pubmed: 21399628
Nat Med. 2015 Jul;21(7):751-9
pubmed: 26099045
Nature. 2014 Aug 14;512(7513):155-60
pubmed: 25079324
Leukemia. 2015 Dec;29(12):2390-2
pubmed: 26108694
Blood Adv. 2019 Feb 12;3(3):339-349
pubmed: 30709865
Exp Hematol. 2014 Jun;42(6):457-63
pubmed: 24495871
Nat Med. 2018 Aug;24(8):1167-1177
pubmed: 30013198
Blood. 2017 Aug 10;130(6):732-741
pubmed: 28588019
Lancet Oncol. 2017 Jan;18(1):100-111
pubmed: 27923552
Sci Transl Med. 2015 Apr 1;7(281):281re2
pubmed: 25834112
N Engl J Med. 2005 Jan 20;352(3):254-66
pubmed: 15659725
Nat Commun. 2019 Jun 21;10(1):2750
pubmed: 31227714
Biol Blood Marrow Transplant. 2018 Jul;24(7):1514-1520
pubmed: 29448058
Nature. 2019 May;569(7757):576-580
pubmed: 31092926
Nucleic Acids Res. 2013 Sep;41(17):e165
pubmed: 23892400

Auteurs

Kiyomi Morita (K)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Feng Wang (F)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Katharina Jahn (K)

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
SIB Swiss Institute of Bioinformatics, Basel, Switzerland.

Tianyuan Hu (T)

Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.

Tomoyuki Tanaka (T)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Yuya Sasaki (Y)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jack Kuipers (J)

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland.
SIB Swiss Institute of Bioinformatics, Basel, Switzerland.

Sanam Loghavi (S)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sa A Wang (SA)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Yuanqing Yan (Y)

Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Ken Furudate (K)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Oral and Maxillofacial Surgery, Hirosaki University Graduate School of Medicine, Aomori, Japan.

Jairo Matthews (J)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Latasha Little (L)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Curtis Gumbs (C)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jianhua Zhang (J)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Xingzhi Song (X)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Erika Thompson (E)

Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Keyur P Patel (KP)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Carlos E Bueso-Ramos (CE)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Courtney D DiNardo (CD)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Farhad Ravandi (F)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Elias Jabbour (E)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Michael Andreeff (M)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Jorge Cortes (J)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Kapil Bhalla (K)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Guillermo Garcia-Manero (G)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Hagop Kantarjian (H)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Marina Konopleva (M)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Daisuke Nakada (D)

Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Nicholas Navin (N)

Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Niko Beerenwinkel (N)

Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland. niko.beerenwinkel@bsse.ethz.ch.
SIB Swiss Institute of Bioinformatics, Basel, Switzerland. niko.beerenwinkel@bsse.ethz.ch.

P Andrew Futreal (PA)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. afutreal@mdanderson.org.

Koichi Takahashi (K)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ktakahashi@mdanderson.org.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ktakahashi@mdanderson.org.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH